BioSpace News Archive

Invivyd, Inc. announced dosing of the first participants in a Phase 1 healthy volunteer trial of VYD222, a novel monoclonal antibody candidate for COVID-19.

Adverum Biotechnologies, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular degeneration (wet AMD).

Nkarta, Inc. announced that Nadir Mahmood, PhD, has resigned his position as chief financial and business officer to serve as the chief executive officer of a private biotechnology company.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its fourth quarter and full-year 2022 operating and financial results and reviewed recent business highlights.

ProSomnus, Inc., a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea, announced financial results for the fourth quarter and fiscal year ended December 31, 2022.

Evogene Ltd. announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission.

ThermoGenesis Holdings, Inc. reported financial and operating results for the year ended December 31, 2022 and provided a corporate strategic update.

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2022 and provides a business update.

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) today announced financial results and recent corporate highlights for the full-year ended December 31, 2022.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.